Fundamental Analysis of IMMUNEERING CORP - CLASS A(NASDAQ:IMRX) stock

Fundamental Rating

Taking everything into account, IMRX scores 2 out of 10 in our fundamental rating. IMRX was compared to 586 industry peers in the Biotechnology industry. While IMRX has a great health rating, there are worries on its profitability. IMRX does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year IMRX has reported negative net income.

In the past year IMRX has reported a negative cash flow from operations.

In the past 5 years IMRX always reported negative net income.

IMRX had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

IMRX has a Return On Assets (-52.13%) which is in line with its industry peers.

Looking at the Return On Equity, with a value of -59.04%, IMRX is in the better half of the industry, outperforming 60.51% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-52.13%
ROE	-59.04%
ROIC	N/A

ROA(3y)-37.84%

ROA(5y)-42.51%

ROE(3y)-42.16%

ROE(5y)-50.14%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

IMRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

IMRX does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, IMRX has more shares outstanding

IMRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

IMRX has an Altman-Z score of -0.98. This is a bad value and indicates that IMRX is not financially healthy and even has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of -0.98, IMRX is in line with its industry, outperforming 54.02% of the companies in the same industry.

IMRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-0.98

ROIC/WACCN/A

WACC9.02%

2.3 Liquidity

IMRX has a Current Ratio of 11.35. This indicates that IMRX is financially healthy and has no problem in meeting its short term obligations.

Looking at the Current ratio, with a value of 11.35, IMRX belongs to the top of the industry, outperforming 80.85% of the companies in the same industry.

A Quick Ratio of 11.35 indicates that IMRX has no problem at all paying its short term obligations.

IMRX has a better Quick ratio (11.35) than 81.03% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	11.35
Quick Ratio	11.35

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 3.61% over the past year.

The Revenue for IMRX has decreased by -100.00% in the past year. This is quite bad

EPS 1Y (TTM)3.61%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q3.92%

Revenue 1Y (TTM)-100%

Revenue growth 3YN/A

Revenue growth 5YN/A

Revenue growth Q2QN/A

3.2 Future

IMRX is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 4.89% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y-4.76%

EPS Next 2Y-0.83%

EPS Next 3Y-3.89%

EPS Next 5Y4.89%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IMRX. In the last year negative earnings were reported.

Also next year IMRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A cheap valuation may be justified as IMRX's earnings are expected to decrease with -3.90% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-0.83%

EPS Next 3Y-3.89%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

IMRX does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

IMMUNEERING CORP - CLASS A

NASDAQ:IMRX (5/17/2024, 7:06:05 PM)

After market: 1.48 +0.01 (+0.68%)

1.47

-0.07 (-4.55%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap43.59M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-52.13%
ROE	-59.04%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	11.35
Quick Ratio	11.35
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)3.61%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y-4.76%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-100%

Revenue growth 3YN/A

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

IMMUNEERING CORP - CLASS A (IMRX)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens